Sage Therapeutics Statistics
Total Valuation
GeoVax Labs has a market cap or net worth of $19.68 million. The enterprise value is $16.59 million.
Important Dates
The last earnings date was Monday, July 28, 2025, after market close.
| Earnings Date | Jul 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GeoVax Labs has 25.36 million shares outstanding. The number of shares has increased by 413.99% in one year.
| Current Share Class | 25.36M |
| Shares Outstanding | 25.36M |
| Shares Change (YoY) | +413.99% |
| Shares Change (QoQ) | +28.48% |
| Owned by Insiders (%) | 0.31% |
| Owned by Institutions (%) | 7.83% |
| Float | 25.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.37 |
| Forward PS | n/a |
| PB Ratio | 4.38 |
| P/TBV Ratio | 6.98 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.70 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.03
| Current Ratio | 2.03 |
| Quick Ratio | 1.43 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,776.83 |
Financial Efficiency
Return on equity (ROE) is -9,690.24% and return on invested capital (ROIC) is -4,780.78%.
| Return on Equity (ROE) | -9,690.24% |
| Return on Assets (ROA) | -331.15% |
| Return on Invested Capital (ROIC) | -4,780.78% |
| Return on Capital Employed (ROCE) | -886.97% |
| Revenue Per Employee | $361,356 |
| Profits Per Employee | -$1.46M |
| Employee Count | 17 |
| Asset Turnover | 1.30 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -59.58% in the last 52 weeks. The beta is 3.36, so GeoVax Labs's price volatility has been higher than the market average.
| Beta (5Y) | 3.36 |
| 52-Week Price Change | -59.58% |
| 50-Day Moving Average | 0.87 |
| 200-Day Moving Average | 1.56 |
| Relative Strength Index (RSI) | 49.71 |
| Average Volume (20 Days) | 1,990,204 |
Short Selling Information
The latest short interest is 2.47 million, so 9.74% of the outstanding shares have been sold short.
| Short Interest | 2.47M |
| Short Previous Month | 3.01M |
| Short % of Shares Out | 9.74% |
| Short % of Float | 9.77% |
| Short Ratio (days to cover) | 0.73 |
Income Statement
In the last 12 months, GeoVax Labs had revenue of $6.14 million and -$24.81 million in losses. Loss per share was -$2.29.
| Revenue | 6.14M |
| Gross Profit | -18.95M |
| Operating Income | -25.02M |
| Pretax Income | -26.92M |
| Net Income | -24.81M |
| EBITDA | -24.94M |
| EBIT | -25.02M |
| Loss Per Share | -$2.29 |
Full Income StatementBalance Sheet
The company has $3.09 million in cash and n/a in debt, giving a net cash position of $3.09 million or $0.12 per share.
| Cash & Cash Equivalents | 3.09M |
| Total Debt | n/a |
| Net Cash | 3.09M |
| Net Cash Per Share | $0.12 |
| Equity (Book Value) | 2.82M |
| Book Value Per Share | 0.18 |
| Working Capital | 2.61M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$27.35 million and capital expenditures -$48,265, giving a free cash flow of -$27.40 million.
| Operating Cash Flow | -27.35M |
| Capital Expenditures | -48,265 |
| Free Cash Flow | -27.40M |
| FCF Per Share | -$1.08 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -407.34% |
| Pretax Margin | -403.80% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GeoVax Labs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -413.99% |
| Shareholder Yield | -413.99% |
| Earnings Yield | -126.05% |
| FCF Yield | -139.23% |
Analyst Forecast
The average price target for GeoVax Labs is $10.50, which is 1,253.09% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.50 |
| Price Target Difference | 1,253.09% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 31, 2024. It was a reverse split with a ratio of 1:15.
| Last Split Date | Jan 31, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
GeoVax Labs has an Altman Z-Score of -46.02 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -46.02 |
| Piotroski F-Score | 3 |
